Literature DB >> 29449693

Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis.

Hualin Zhang1, Yang Song1, Huimin Yang2, Zhiyan Liu3, Lifen Gao1, Xiaohong Liang4, Chunhong Ma5,6.   

Abstract

T-cell immunoglobulin and mucin-domain containing-3 (Tim-3), mediating immune exhaustion in tumor microenvironment, has become a promising target for tumor therapy. However, the exact mechanisms for tumor cell-intrinsic Tim-3 in tumor development and its potential contribution in Tim-3-targeted therapy strategy have not been elucidated yet. In this study, we showed that human liver cancer tissues contained high ratio of Tim-3-expressing hepatocytes, and cytokines rich in tumor microenvironment and HBV involved in Tim-3 upregulation in malignant hepatocytes. We demonstrated that hepatocyte-specific Tim-3 overexpression enhances tumor cell growth, whereas Tim-3 inhibition on malignant hepatocytes by anti-Tim-3 antibodies or RNAi suppresses tumor growth both in vitro and in Tim-3 knockout mice. Mechanistically, the hepatocyte-Tim-3 receptor activates NF-κB phosphorylation, which in turn stimulates IL-6 secretion and STAT3 phosphorylation. Our results identify tumor cell-intrinsic functions of Tim-3 in tumorigenesis and suggest that blocking Tim-3 in tumor cells might contribute to the clinical efficacy of anti-Tim-3 antibody treatment in the future tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29449693     DOI: 10.1038/s41388-018-0140-4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection.

Authors:  Wenjing Yi; Peixin Zhang; Yan Liang; Yun Zhou; Huanjun Shen; Chao Fan; Jonathan P Moorman; Zhi Q Yao; Zhansheng Jia; Ying Zhang
Journal:  Immunology       Date:  2016-12-07       Impact factor: 7.397

2.  Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.

Authors:  Shin Foong Ngiow; Bianca von Scheidt; Hisaya Akiba; Hideo Yagita; Michele W L Teng; Mark J Smyth
Journal:  Cancer Res       Date:  2011-03-23       Impact factor: 12.701

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B.

Authors:  Ying Ju; Nan Hou; Jing Meng; Xiaoyan Wang; Xiaoning Zhang; Di Zhao; Ying Liu; Faliang Zhu; Lining Zhang; Wensheng Sun; Xiaohong Liang; Lifen Gao; Chunhong Ma
Journal:  J Hepatol       Date:  2010-01-06       Impact factor: 25.083

5.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

6.  Prognostic implication of TIM-3 in clear cell renal cell carcinoma.

Authors:  J Yuan; B Jiang; H Zhao; Q Huang
Journal:  Neoplasma       Date:  2014       Impact factor: 2.575

Review 7.  Cellular and molecular mechanisms of hepatocellular carcinoma: an update.

Authors:  Rajagopal N Aravalli; Erik N K Cressman; Clifford J Steer
Journal:  Arch Toxicol       Date:  2012-09-25       Impact factor: 5.153

8.  Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer.

Authors:  Encheng Zhou; Qing Huang; Ji Wang; Chengfeng Fang; Leilei Yang; Min Zhu; Jianhui Chen; Lihua Chen; Milian Dong
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT.

Authors:  F Luan; H Liu; L Gao; J Liu; Z Sun; Y Ju; N Hou; C Guo; X Liang; L Zhang; W Sun; C Ma
Journal:  Gut       Date:  2009-08-02       Impact factor: 23.059

10.  TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway.

Authors:  Brian Tomkowicz; Eileen Walsh; Adam Cotty; Raluca Verona; Nina Sabins; Fred Kaplan; Sandy Santulli-Marotto; Chen-Ni Chin; Jill Mooney; Russell B Lingham; Michael Naso; Timothy McCabe
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

View more
  25 in total

1.  Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells.

Authors:  Yizi Cong; Yuxin Cui; Shiguang Zhu; Jianqiao Cao; Haidong Zou; Tracey A Martin; Guangdong Qiao; Wenguo Jiang; Zhigang Yu
Journal:  Chin J Cancer Res       Date:  2020-10-31       Impact factor: 5.087

Review 2.  Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.

Authors:  Mahsa Pourhamzeh; Samieh Asadian; Hamed Mirzaei; Azita Minaei; Elahe Shahriari; Anastasia Shpichka; Hamidreza Aboulkheyr Es; Peter Timashev; Moustapha Hassan; Massoud Vosough
Journal:  Mol Cell Biochem       Date:  2022-06-16       Impact factor: 3.396

3.  Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles.

Authors:  Chenghua Song; Jia Zhang; Ruichao Wen; Qingshan Li; Jiaxuan Zhou; Zheng Wu; Yi Lv; Rongqian Wu
Journal:  Mater Today Bio       Date:  2022-07-06

4.  SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer.

Authors:  Li Zhang; Sijuan Tian; Minyi Zhao; Ting Yang; Shimin Quan; Qing Yang; Lihua Song; Xiaofeng Yang
Journal:  Cancer Cell Int       Date:  2020-07-20       Impact factor: 5.722

Review 5.  Cytokines, breast cancer stem cells (BCSCs) and chemoresistance.

Authors:  Weilong Chen; Yuanyuan Qin; Suling Liu
Journal:  Clin Transl Med       Date:  2018-09-03

6.  Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-κB/TNF-α pathway.

Authors:  Huimin Yang; Tingting Xie; Dengren Li; Xianhong Du; Tixiao Wang; Chunyang Li; Xiaojia Song; Leiqi Xu; Fan Yi; Xiaohong Liang; Lifen Gao; Xiangdong Yang; Chunhong Ma
Journal:  Mol Metab       Date:  2019-02-26       Impact factor: 7.422

7.  Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells.

Authors:  Qin Zhao; Wen-Rong Yang; Xiao-Hong Wang; Gai-Qin Li; Lei-Qi Xu; Xiao Cui; Yang Liu; Xiu-Li Zuo
Journal:  World J Gastroenterol       Date:  2019-09-28       Impact factor: 5.742

8.  Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection.

Authors:  Fang Li; Na Li; Jiao Sang; Xiude Fan; Huan Deng; Xiaoge Zhang; Qunying Han; Yi Lv; Zhengwen Liu
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989

9.  Significance of STAT3 in Immune Infiltration and Drug Response in Cancer.

Authors:  Wei Chen; Xiaoshuo Dai; Yihuan Chen; Fang Tian; Yanyan Zhang; Qiushuang Zhang; Jing Lu
Journal:  Biomolecules       Date:  2020-05-29

Review 10.  Tim-3 expression and its role in hepatocellular carcinoma.

Authors:  Feifei Liu; Yanning Liu; Zhi Chen
Journal:  J Hematol Oncol       Date:  2018-10-11       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.